Nine potential blockbuster treatments expected to be approved in 2022

Say goodbye to 2021.

The report pointed out that there are 10 innovative therapies that may be approved in 2022 and are expected to become blockbusters in the future

▲ 9 blockbuster therapies that are expected to be approved in 2022 (data source: reference [1], drawing by WuXi AppTec's content team;

▲ 9 blockbuster therapies that are expected to be approved in 2022 (data source: reference [1], drawing by WuXi AppTec's content team;

Donanemab (Lilly)

Donanemab (Lilly)

In 2021, the advent of Alzheimer's disease treatment Aduhelm (aducanumab) is one of the focuses of the industry's most attention, and it is also the beginning of a new wave of Alzheimer's disease research and development

In June last year, this therapy was approved by the US FDA as a breakthrough therapy

Tirzepatide (Lilly)

Tirzepatide is a GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor dual agonist, which is expected to treat diabetes

Tirzepatide is a GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor dual agonist, which is expected to treat diabetes

Gantenerumab (Roche)

In the WuXi AppTec content team’s "Top Ten Clinical Trials to Watch in 2022", it is mentioned that therapies represented by donanemab and gantenerumab will become a new wave of treatment for Alzheimer's disease

This anti-β-amyloid antibody therapy under development has been approved by the US FDA as a breakthrough therapy .

Deucravacitinib (Bristol-Myers Squibb)

In November 2021, Bristol-Myers Squibb announced that the US FDA has accepted a new drug application (NDA) for the potential "first-in-class" oral selective TYK2 inhibitor deucavacitinib for the treatment of moderate/severe plaque psoriasis in adults

The press release stated that deucravacitinib is expected to be the first approved TYK2 inhibitor

Bardoxolone (Reata)

Bardoxolone is an oral nuclear factor red blood cell 2 related factor (Nrf2) agonist

Bardoxolone is an oral nuclear factor red blood cell 2 related factor (Nrf2) agonist

Vutrisiran (Alnylam)

Vutrisiran is a subcutaneously administered RNAi therapeutic drug used to treat transthyretin-mediated (ATTR) amyloidosis, including hATTR and wild-type ATTR (wtATTR) amyloidosis

In the phase 3 trial, this therapy achieved the primary endpoint and all secondary endpoints

Mavacamten (Bristol-Myers Squibb)

Mavacamten is a potential "first-in-class" cardiovascular drug

Potential "first-in-class" cardiovascular drugs that can inhibit myocardial myosin for the treatment of obstructive hypertrophic cardiomyopathy (oHCM)

Cilta-cel (Johnson & Johnson/Legendary Creatures)

Carvykti (cilta-cel), jointly developed by Janssen and Legend Bio, is a CAR-T therapy targeting B cell maturation antigen (BCMA)
.
Data released last year at the 63rd American Society of Hematology (ASH) annual meeting showed that cilta-cel exhibits long-lasting anti-cancer activity in the treatment of patients with relapsed/refractory multiple myeloma who have received a variety of previous treatments
.
At a median follow-up time of 22 months, 83% of patients achieved strict complete remission
.
This value is a further improvement from 80% when the median follow-up time is 18 months
.
Cilta-cel has obtained the priority review qualification granted by the US FDA, and the PDUFA date is February 28, 2022
.
The European Union is also expected to approve this therapy in the first quarter of this year
.

At a median follow-up time of 22 months, 83% of patients achieved strict complete remission
.

Adagrasib (Mirati Therapeutics)

Adagrasib (Mirati Therapeutics)

Adagrasib is a highly specific and potent oral KRAS G12C inhibitor .
It has been granted a breakthrough therapy designation by the US FDA for the treatment of treated non-small cell lung cancer patients with KRAS G12C mutations
.
In phase 2 clinical trials, this therapy achieved an objective response rate (ORR) of 43% and a disease control rate (DCR) of 80%
.
It is worth mentioning that 98.
3% of patients treated with adagrasib have already received immunotherapy and chemotherapy, so it is a new hope for these patient groups
.
Earlier this year, Mirati plans to release more detailed data
.
The Evaluate report pointed out that the company may also use accelerated approval
.

Adagrasib is a highly specific and potent oral KRAS G12C inhibitor.
It is worth mentioning that 98.
3% of patients treated with adagrasib have already received immunotherapy and chemotherapy, so it is a new product for these patient groups.
Hope
.

In the new year, how many potential blockbuster treatments will come out as predicted? What innovative therapies will come out to benefit patients around the world? Follow WuXi AppTec's WeChat official account, we will witness together in the new year
.

Reference materials:

Reference materials:

[1] Evaluate Vantage 2022 Preview, Retrieved January 2, 2022, from https:// Evaluate Vantage 2022 Preview, Retrieved January 2, 2022, from https:// [2] Historical reports of related therapies on the official account of WuXi AppTec

[2] Historical reports of related therapies on the official account of WuXi AppTec